1. The biotech resurrection continues — Industry and FDA begin to hammer out PDUFA VII details — JNJ single-shot COVID-19 vaccine shows early promise — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Attn Investors and Upper Management

Discussion in 'Johnson & Johnson' started by anonymous, Aug 10, 2020 at 7:34 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Despite working from home, we, the sales reps can be successful and increase sales. However, lower and mid level management are making things difficult because they are panicked about the future of their position. I am on the Janssen team and I spend 1/3 of my day making calls. The other 2/3 are spent on conference calls, completing redundant spreadsheets and making cutesy videos. The excessive number of conference calls has got to stop. I realize the district managers have nothing better to do; but to bombard us with conference calls is counter productive. If the company had a two week moratorium on conference calls, sales would increase.

    In addition, an invalidated rumor is that the Syneos reps are being told to fluff their sales calls in order for the contract to continue. Can the contract be terminated due to fraud? I actually feel sorry for them as they have more conference calls than we do.
     

  2. anonymous

    anonymous Guest

    Unfortunately you just told upper management they only need 1/3 of the reps.
     
  3. anonymous

    anonymous Guest

    No, the way I interpret it is- if they weren’t on so many nonsensical conference calls they could spend more of their time impacting business.
     
  4. anonymous

    anonymous Guest


    I do too, but I worked in corp and understand how those mental midgets think. They’re desperate to find new cost savings “initiatives” and are looking for a rationale to reduce rep income. Corp thinks what we do is easy.
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

    Corporate is right. What you do is easy, you mental "vertically challenged" millennial.

    Here's the truth about J&J pharmaceutical sales and marketing:
    • minimal impact in any given year these days (i.e. 5-8%) of total revenue
    • marketing makes more of an impact in all the other activities via media, etc.
    • you are legally constrained, "chained" to the package insert if your behaving legally and ethically
    • no one really needs your food, and samples are good but there are other ways
    • no one benefits from your lack of medical wisdom and insight
    • if you can keep finding ways to pay me off, I'll play some small ball says your OL and researcher
    • only thing that matters from J&J is deep pockets; and they ain't yours
     
  7. anonymous

    anonymous Guest

    Ah, our impact continues to decline well below 5% for established brands. New prodt. launches we make a difference. Sometimes big difference. But everything is changing after all this, conference call heaven or not.